References
- Citrome L. Differential diagnosis of psychosis: a brief guide for the primary care physician. Postgrad Med 1989; 85(4):273–80
- Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45:789–96
- Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329(3):162–7
- Clozaril (clozapine). Patient management handbook. East Hanover, NJ: Sandoz Pharmaceuticals Corp, 1995
- Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152(2):179–82
- McEvoy JP. Dosing issues: target symptoms and dose response. Psych Ann 1995; 25(5):297–300
- Meltzer HY. Clozapine. Is another view valid? (Editorial) Am J Psychiatry 1995; 152(6):821–5
- Carpenter WT, Conley RR, Buchanan RW, et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152(6):827–32
- Friedman LJ, Tabb SE, Worthington JJ, et al. Clozapine—a novel antipsychotic agent. (Letter) N Engl J Med 1991; 325:518
- Klimke A, Klieser E. Sudden death after intravenous application of lorazepam in a patient treated with clozapine. (Letter) Am J Psychiatry 1994; 151(5):780
- Cobb CD, Anderson CB, Seidel DR. Possible interaction between clozapine and lorazepam. (Letter) Am J Psychiatry 1991; 148(11):1606–7
- Clozaril product information. In: Physicians' Desk Reference. 50th ed. Mont-vale, NJ: Medical Economics Co, 1996, pp 2252–55
- Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153(6):820–22
- Marder SR, Melbach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6):825–35
- Jibson MD, Tandon R. Special report: a summary of research findings on the new antipsychotic drugs. Directions Psychiatry 1996; 16(May):1–8
- Ereshefsky L, Mack RJ, Morris DD, et al. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. (Abstr) Psychopharmacology Bull 1996; 32(3):441
- Tollefson G, Beasley C, Tran P, et al. Olanzapine versus haloperidol: acute results of the multi-center international trial. (Abstr) Psychopharmacology Bull 1996; 32(3):401
- Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial. (Abstr) Psychopharmacology Bull 1996; 32(3):391
- Hong WW, Arvanitis LA, Miller BG, et al. The atypical profile of ICI 204,636 is supported by its lack of induction of extrapyramidal symptoms. (Abstr) Psychopharmacology Bull 1996; 32(3):458
- Harrigan EP, Reeves K. The efficacy and safety of two fixed doses of ziprasidone in schizophrenia. (Abstr) Psychopharmacology Bull 1996; 32(3):456